Posted by Michael Wonder on 24 Dec 2025
Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
23 December 2025 - Approval based on the LUNA 3 Phase 3 study that demonstrated rapid and durable platelet response and improvements in other immune thrombocytopenia symptoms.
The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton’s tyrosine kinase inhibitor, as a new treatment for immune thrombocytopenia in adult patients who are refractory to other treatments.
